Inovio Pharmaceuticals (NASDAQ:INO) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Inovio Pharmaceuticals (NASDAQ:INO) announced its earnings results on Wednesday. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.02, FiscalAI reports.

Here are the key takeaways from Inovio Pharmaceuticals’ conference call:

• Inovio said its INO-3107 BLA remains on track for the October 30, 2026 PDUFA date, and the FDA’s mid-cycle review raised no new significant issues. Management also said the agency reiterated plans to schedule the informal meeting on accelerated-approval eligibility.
• The company continues to believe INO-3107 supports accelerated approval based on its phase I/II data, citing large reductions in surgeries, a favorable safety profile, and a differentiated mechanism that may help patients not served by the current approved therapy.
• Inovio is building commercial readiness ahead of a potential launch, including partnerships for logistics, specialty distribution, pharmacy, and patient support. Management said it plans to commercialize with a contract sales organization and expects to benefit from learnings from the competitor’s launch.
• The company strengthened its balance sheet with a April equity offering that raised about $16 million net. Inovio ended Q1 with $37.7 million in cash and short-term investments and said its runway now extends into Q1 2027, beyond the expected PDUFA date.
• Beyond INO-3107, Inovio highlighted progress on its broader pipeline, including an Akeso/Dana-Farber collaboration in glioblastoma and advancement of its DPROT platform for rare-disease applications such as hemophilia A, Fabry disease, and hypophosphatasia.

Inovio Pharmaceuticals Stock Down 0.4%

Shares of NASDAQ INO traded down $0.01 during trading on Thursday, hitting $1.34. 1,022,989 shares of the company traded hands, compared to its average volume of 1,989,332. The firm has a market capitalization of $92.70 million, a P/E ratio of -0.79 and a beta of 1.43. The company has a 50-day moving average price of $1.39 and a 200-day moving average price of $1.72. Inovio Pharmaceuticals has a 1 year low of $1.03 and a 1 year high of $2.98.

Institutional Investors Weigh In On Inovio Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the company. Marshall Wace LLP acquired a new position in shares of Inovio Pharmaceuticals in the 4th quarter valued at about $143,000. Hudson Bay Capital Management LP purchased a new position in Inovio Pharmaceuticals in the fourth quarter valued at approximately $88,000. CIBC Private Wealth Group LLC lifted its position in Inovio Pharmaceuticals by 357,042.9% during the fourth quarter. CIBC Private Wealth Group LLC now owns 50,000 shares of the biopharmaceutical company’s stock valued at $87,000 after buying an additional 49,986 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Inovio Pharmaceuticals by 1,667.1% during the third quarter. JPMorgan Chase & Co. now owns 65,206 shares of the biopharmaceutical company’s stock worth $153,000 after buying an additional 61,516 shares during the period. Finally, Jane Street Group LLC increased its position in shares of Inovio Pharmaceuticals by 221.2% in the second quarter. Jane Street Group LLC now owns 39,683 shares of the biopharmaceutical company’s stock worth $81,000 after acquiring an additional 27,329 shares in the last quarter. Hedge funds and other institutional investors own 26.79% of the company’s stock.

Analyst Ratings Changes

INO has been the topic of several analyst reports. Wall Street Zen upgraded Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, March 14th. Oppenheimer reiterated an “outperform” rating on shares of Inovio Pharmaceuticals in a research note on Friday, March 13th. Finally, Weiss Ratings lowered Inovio Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 6th. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Inovio Pharmaceuticals has an average rating of “Hold” and a consensus price target of $4.50.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.